Eric Dube, Ph.D., the CEO who rebranded Travere Therapeutics and oversaw the launch of its rare kidney disease drug Filspari, will ...

The White House is threatening yet another change to the childhood vaccine schedule in line with Secretary of Health and Human Services secretary Robert F. Kennedy Jr.’s MAHA agenda.  | The president ...

"These Phase 3 results build on the established efficacy of Caplyta in bipolar depression and represent an important step in evaluating its potential to address both depressive and acute manic ...

IntraBio is on a roll with its expansion plans for chemically altered amino acid, Aqneursa. | IntraBio's streak of success in the rare neurological category continues, as the drugmaker racks up a ...

Novo CEO Mike Doustdar faced a tough crowd as the Danish pharma gathered investors in London this morning for the compan | With reports leaking out of investor discontent, CEO Mike Doustdar opened ...

Bayer has decided to offload its aging cancer drug Stivarga to German compatriot Grünenthal as competition mounts. | Bayer has decided to offload its aging cancer drug Stivarga to German compatriot ...

For years, sponsors have pursued incremental gains in clinical development through process improvement and task-based automation. But as protocols become more complex and operational demands intensify ...

Public Citizen stressed that it supports efforts to lower drug costs for people in America, while caveating that the MFN deals as understood—and with added color from companies on the policy’s ...

Eli Lilly is sharpening its competitive edge in the crowded oral SERD arena as the FDA has approved a combination of its ...

European drug regulators just wrapped another stack of reviews, a | The CHMP recommendation for Novo's next gen hemophilia A treatment was one of several noteworthy endorsements made by the EU agency ...

Comedian Damon Wayans, a patient advocate and spokesperson for the humor-forward Genentech campaign “All Eyes of DME,” said that element is at the heart of his work with the Roche subsidiary to raise ...

Most drug licensing deals with China will be safe from rules being drafted by the U.S. Treasury Department, Reuters reports.